PharmaTelevision - Novo Nordisk: Tomas Landh elaborates on their quest to find new innovative therapies and new targets for treating diabetes

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Novo Nordisk: Tomas Landh elaborates on their quest to find new innovative therapies and new targets for treating diabetes

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this episode of PharmaTelevision News Review, Fintan Walton talks to Tomas Landh, Director Strategy and Sourcing of Novo Nordisk.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Tomas Landh's functions as Director of Strategy and Sourcing

Fintan Walton:

Hello and welcome to PharmaTelevision News Review here at BioPharm America, in Boston. On this show I have Tomas Landh, who is Director of Strategy and Sourcing at Novo Nordisk based in Denmark, welcome.

Tomas Landh:

Thank you very much it's a pleasure to be here.

Fintan Walton:

It's pleasure to have you and to talk a little bit about your work at Novo Nordisk, obviously Novo Nordisk is a very famous company specifically in the area of diabetes it's one of its key areas of activity, first of all tell us where do you fit within the Novo Nordisk organization and what is your function?

Tomas Landh:

So my function is primarily to scout new opportunities, therapeutic opportunities for Novo Nordisk Diabetes Research Unit, basic opening in [Indiscernable 00.00.59] where we have the majority of our R&D activities globally and I am also very much involved in new strategic initiatives increasing the awareness of what we are looking for external partnership.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Fintan Walton

Dr Fintan Walton is the Founder and CEO of PharmaVentures . After completing his doctoral research on the genetics of cell proliferation at the University of Michigan(US)and Trinity College (Dublin, Ireland), Dr Walton gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc (1982-1992).

Tomas Landh

Officer

Tomas Landh is presently Director (Strategy and Sourcing) at Novo Nordisk, Diabetes Research Unit, where he is responsible for scouting and evaluation of in particular, protein therapeutics and new drug delivery technologies. Tomas is also deeply involved in fostering partnerships with academia and biotech industries and in strategic initiatives with the Diabetes Research Unit.

PharmaVentures

PharmaVentures is a corporate finance and transactions advisory firm that has served hundreds of clients worldwide in relation to their strategic deal making in the pharmaceutical, life science and healthcare sectors. Our key offerings include: Transactions / deal negotiations; Product / technology valuations; Deal term advice; Due diligence & expert reports; Strategy formulation; Alliance management; and Expert opinion for litigation/arbitration cases. PharmaVentures provides the global expertise to ensure our clients generate the highest possible return on investment from all their deal making activities. We have experience of all therapeutic areas and can offer advice on both product and technology commercialisation.

Novo Nordisk

Novo Nordisk is a global healthcare company with 87 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 30,000 employees in 76 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO).